{
    "clinical_study": {
        "@rank": "129329", 
        "arm_group": [
            {
                "arm_group_label": "atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Intervention is be atorvastatin  (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.\nPBMC will be collected for immune activation assays using flowcytometry"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry"
            }
        ], 
        "brief_summary": {
            "textblock": "We hypothesise that atorvastatin changes immune activation among HAART-treated adults with\n      suboptimal CD4 recovery by 25%"
        }, 
        "brief_title": "Atorvastatin for HAART Suboptimal Responders", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acquired Immune Deficiency Syndrome Virus", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators have previously shown that up to 40% of HAART-treated adults have\n      suboptimal CD4 recovery despite viral suppression. The investigators have also shown that\n      immune activation and exhaustion are significantly higher among patients that do not exhibit\n      satisfactory rise in CD4 counts despite viral suppression (suboptimal responders); when\n      compared with their counterparts with viral suppression and satifactory CD4 count recovery\n      (optimal responders). Given that atorvastatin changes immune activation in this pilot study,\n      then larger studies can be done to understand its effect on CD4 count increase among\n      suboptimal responders."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  HIV-infected adults on antiretroviral therapy for at least 6 years with sustained\n             viral suppression (viral load<400 copies)\n\n          -  CD4 increase below 300 cells (difference between current and baseline CD4 count).\n\n        Exclusion Criteria:\n\n          -  History of an opportunistic infection within the previous six months\n\n          -  Pregnancy\n\n          -  History of myositis\n\n          -  History of ingestion of lipid-lowering agents at the baseline visit\n\n          -  Use of therapeutic agents known to have substantial drug-drug interactions with\n             statins Individuals on PI-containing HAART"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766076", 
            "org_study_id": "HS1258"
        }, 
        "intervention": [
            {
                "arm_group_label": "atorvastatin", 
                "description": "PBMC collected for immune activation assays using flowcytometry", 
                "intervention_name": "'atorvastatin, Lipitor\u00ae'", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "PBMC collected for immune activation assays using flowcytometry", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "immune activation", 
            "antiretroviral therapy", 
            "atorvastatin", 
            "immune exhaustion", 
            "adults", 
            "Africa"
        ], 
        "lastchanged_date": "January 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kampala", 
                    "country": "Uganda", 
                    "state": "East Africa"
                }, 
                "name": "Infectious Diseases Institute"
            }
        }, 
        "location_countries": {
            "country": "Uganda"
        }, 
        "number_of_arms": "2", 
        "official_title": "Use of Atorvastatin as Adjuvant Therapy Among Suboptimal Responders to Antiretroviral Therapy in an African Cohort of HAART-treated Adults: A Randomised Controlled Trial", 
        "overall_contact": {
            "email": "drdamalie@yahoo.com", 
            "last_name": "Damalie Nakanjako, MD, PhD", 
            "phone": "+256772411273"
        }, 
        "overall_contact_backup": {
            "email": "ssinabulya@yahoo.com", 
            "last_name": "Isaac Ssinabulya, MD"
        }, 
        "overall_official": {
            "affiliation": "Makerere University", 
            "last_name": "Damalie Nakanjako, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Uganda: National Council for Science and Technology", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Immune activation levels will be measured before and after administration of the intervention drug (atorvastatin, Lipitor\u00ae) and will be compared among patients that take drug and placebo.", 
            "measure": "Change of immune activation levels by 25% after 12 weeks of atorvastatin 80mg daily", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "reference": [
            {
                "PMID": "21325137", 
                "citation": "Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, Brandt C, Vita J, Decker CF, Sklar P, Bavaro M, Tasker S, Follmann D, Maldarelli F. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011 Mar 15;203(6):756-64. doi: 10.1093/infdis/jiq115. Epub 2011 Feb 15."
            }, 
            {
                "PMID": "21299909", 
                "citation": "Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, Nabatanzi R, Kamya MR, Cao H. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis. 2011 Feb 8;11:43. doi: 10.1186/1471-2334-11-43."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766076"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Makerere University", 
            "investigator_full_name": "Faculty of Medicine", 
            "investigator_title": "Lecturer", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Makerere University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Makerere University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}